238 related articles for article (PubMed ID: 29320714)
1. A case report of mesenteric heterotopic ossification: Histopathologic and genetic findings.
Amalfitano M; Fyfe B; Thomas SV; Egan KP; Xu M; Smith AG; Kaplan FS; Shore EM; Pignolo RJ
Bone; 2018 Apr; 109():56-60. PubMed ID: 29320714
[TBL] [Abstract][Full Text] [Related]
2. Differential Vascularity in Genetic and Nonhereditary Heterotopic Ossification.
Ware AD; Brewer N; Meyers C; Morris C; McCarthy E; Shore EM; James AW
Int J Surg Pathol; 2019 Dec; 27(8):859-867. PubMed ID: 31250694
[No Abstract] [Full Text] [Related]
3. Endochondral ossification in a case of progressive osseous heteroplasia in a young female child.
Schrander DE; Welting TJ; Caron MM; Schrander JJ; van Rhijn LW; Körver-Keularts I; Schrander-Stumpel CT
J Pediatr Orthop B; 2014 Sep; 23(5):477-84. PubMed ID: 24626099
[TBL] [Abstract][Full Text] [Related]
4. Matrix metalloproteinase-9 deficiency confers resilience in fibrodysplasia ossificans progressiva in a man and mice.
Lounev V; Groppe JC; Brewer N; Wentworth KL; Smith V; Xu M; Schomburg L; Bhargava P; Al Mukaddam M; Hsiao EC; Shore EM; Pignolo RJ; Kaplan FS
J Bone Miner Res; 2024 May; 39(4):382-398. PubMed ID: 38477818
[TBL] [Abstract][Full Text] [Related]
5. Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1.
Whyte MP; Wenkert D; Demertzis JL; DiCarlo EF; Westenberg E; Mumm S
J Bone Miner Res; 2012 Mar; 27(3):729-37. PubMed ID: 22131272
[TBL] [Abstract][Full Text] [Related]
6. Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.
Chakkalakal SA; Shore EM
Methods Mol Biol; 2019; 1891():247-255. PubMed ID: 30414138
[TBL] [Abstract][Full Text] [Related]
7. Heterotopic Ossification: The Keys to the Kingdom.
Kaplan FS; Pignolo RJ; Shore EM
Bone; 2018 Apr; 109():1-2. PubMed ID: 29567209
[No Abstract] [Full Text] [Related]
8. Progressive osseous heteroplasia is not a Mendelian trait but a type 2 segmental manifestation of GNAS inactivation disorders: A hypothesis.
Happle R
Eur J Med Genet; 2016 May; 59(5):290-4. PubMed ID: 27058263
[TBL] [Abstract][Full Text] [Related]
9. Cell Senescence in Heterotopic Ossification.
Pignolo RJ; Kaplan FS; Wang H
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672501
[TBL] [Abstract][Full Text] [Related]
10. Progressive osseous heteroplasia, as an isolated entity or overlapping with Albright hereditary osteodystrophy.
Lin MH; Numbenjapon N; Germain-Lee EL; Pitukcheewanont P
J Pediatr Endocrinol Metab; 2015 Jul; 28(7-8):911-8. PubMed ID: 25894639
[TBL] [Abstract][Full Text] [Related]
11. Progressive osseous heteroplasia in a 5-year-old boy with a novel mutation in exon 2 of GNAS: a case presentation and literature review.
Ma J; Mo W; Sun J; Li Y; Han T; Mao H
BMC Musculoskelet Disord; 2023 Mar; 24(1):247. PubMed ID: 37003989
[TBL] [Abstract][Full Text] [Related]
12. A Three-Generation Pedigree of Multifocal Heterotopic Ossification With Bilateral Involvement.
Liu Y; Zhao XD
Orthopedics; 2021 Jan; 44(1):e139-e145. PubMed ID: 33089331
[TBL] [Abstract][Full Text] [Related]
13. An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva.
Hino K; Zhao C; Horigome K; Nishio M; Okanishi Y; Nagata S; Komura S; Yamada Y; Toguchida J; Ohta A; Ikeya M
Stem Cell Reports; 2018 Nov; 11(5):1106-1119. PubMed ID: 30392977
[TBL] [Abstract][Full Text] [Related]
14. [Fibrodysplasia ossificans progressiva and osteoimmunology].
Katagiri T
Clin Calcium; 2016 May; 26(5):691-8. PubMed ID: 27117614
[TBL] [Abstract][Full Text] [Related]
15. Screening for GNAS genetic and epigenetic alterations in progressive osseous heteroplasia: first Italian series.
Elli FM; Barbieri AM; Bordogna P; Ferrari P; Bufo R; Ferrante E; Giardino E; Beck-Peccoz P; Spada A; Mantovani G
Bone; 2013 Oct; 56(2):276-80. PubMed ID: 23796510
[TBL] [Abstract][Full Text] [Related]
16. Progressive osseous heteroplasia in a 7-year-old girl with osteoma cutis and autoimmune thyroiditis: the importance of investigating GNAS mutations.
Mariani M; Rigante D; Guerriero C; Ricci F; Sani I; Rossodivita A
J Eur Acad Dermatol Venereol; 2016 May; 30(5):905-7. PubMed ID: 25752801
[No Abstract] [Full Text] [Related]
17. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
[TBL] [Abstract][Full Text] [Related]
18. The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator.
Lin H; Shi F; Gao J; Hua P
Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31341010
[TBL] [Abstract][Full Text] [Related]
19. Heterotopic ossification: Mechanistic insights and clinical challenges.
Xu R; Hu J; Zhou X; Yang Y
Bone; 2018 Apr; 109():134-142. PubMed ID: 28855144
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic stem-cell contribution to ectopic skeletogenesis.
Kaplan FS; Glaser DL; Shore EM; Pignolo RJ; Xu M; Zhang Y; Senitzer D; Forman SJ; Emerson SG
J Bone Joint Surg Am; 2007 Feb; 89(2):347-57. PubMed ID: 17272450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
